Company Overview - Changjiang Life Science Technology Group Limited is listed on the Hong Kong Stock Exchange and is a member of the CK Hutchison Group, focusing on the research, manufacturing, commercialization, promotion, sales, and investment in health, pharmaceuticals, diagnostics, and agriculture-related projects and assets [2]. Stock Performance - As of April 14, the Hang Seng Index rose by 2.4%, closing at 21,417.4 points. Changjiang Life Science Technology's stock closed at HKD 0.71 per share, up 16.39%, with a trading volume of 50.66 million shares and a turnover of HKD 33.68 million, showing a volatility of 16.39% [1]. - Over the past month, Changjiang Life Science Technology has seen a cumulative increase of 10.91%, and a year-to-date increase of 48.78%, outperforming the Hang Seng Index's increase of 4.26% [1]. Financial Performance - For the fiscal year ending December 31, 2024, Changjiang Life Science Technology reported total revenue of CNY 5.114 billion, a year-on-year increase of 3.76%. However, the net profit attributable to shareholders was a loss of CNY 117 million, a significant decrease of 833.65% compared to the previous year [1]. - The company's gross profit margin stands at 30.65%, with a debt-to-asset ratio of 67.45% [1]. Industry Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 11.13 times, with a median of 4.85 times. In comparison, Changjiang Life Science Technology has a P/E ratio of -46.33 times, ranking 85th in the industry [1]. - Other companies in the industry have the following P/E ratios: Qianjing Pharmaceutical (0.64), Kingsray Biotechnology (0.98), Baixin International (1.49), Dongrui Pharmaceutical (2.78), and Charoen Pokphand International (4.28) [1].
长江生命科技（00775.HK）4月14日收盘上涨16.39%，成交3368.4万港元